Special Issue

Treatment of Mastitis in Dairy Cattle

Message from the Guest Editor

Bovine mastitis is one of the most costly diseases affecting the dairy industry and is the most common condition affecting dairy cows where antibiotics are used. Also, it is a painful disease that affects animal welfare. Over recent decades, the aims of mastitis treatment have been focused on maximizing cure rates, which has led to relatively simple treatment criteria resulting in predominantly blanket antimicrobial treatment. Not only uncritical substances are used. Only through careful and systematic scientific work can the therapy of mastitis be more targeted, so that comparable or even better cure rates can be achieved with fewer antibiotic doses. This issue seeks manuscripts that will help in the development of an evidence-based targeted antibiotic therapy for mastitis in cattle. This includes not only manuscripts on clinical and pharmacological issues, but also those on decision-making tools, antimicrobial resistance, knowledge transfer in practice, economics of evidence-based therapies and animal welfare aspects. **Keywords**: mastitis therapy, antimicrobial resistance, evidence based antibiotic treatment, bacteriological cure, animal welfare

Guest Editor

Dr. Volker Krömker

Department of Microbiology, Faculty of Mechanical and Bioprocess Engineering, University of Applied Sciences and Arts, 30453 Hannover, Germany

Deadline for manuscript submissions

closed (30 April 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/68471

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI